Educational Administration: Theory and Practice
2024, 30(5), 7984-7992
ISSN: 2148-2403
https://kuey.net/
Research Article

Characterization And In Vivo Efficacy Of Conamax-Derived Antibody Drug Conjugates In Preclinical Cancer Models.

Dr. Manisha Masih Singh[1*], Shilpi Shukla[2], Subhadeep Sasmal[3], Aakansha Sharma[4], Dr. Suchitra S. Mishra[5], Arindam Chatterjee[6], Neelam Wadhwani[7], Subhadas Chatterjee[8]

[1*]Associate Professor, School of Pharmacy, Chouksey Engineering College, Lal khadan, Masturi road, Bilaspur, Chhattisgarh-Pin code - 495004.
[2]Assistant Professor, School of Pharmacy, Chouksey Engineering College, Lal khadan, masturi road, Bilaspur, Chhattisgarh-495004.
[3]Assistant Professor, College address - NSHM Knowledge Campus, 60 BL Saha Road, Kolkata -700008.
[4]Assistant Professor, Siddhi Vinayaka Institute of Technology Sciences, Bilaspur, Chhattisgarh-495001.
[5]Assistant Professor, Dadasaheb Balpande college of Pharmacy, New Swami Samartha Dham Mandir, Besa, Nagpur-440037.
[6]Assistant Professor, Gupta College of Technological Sciences, Ashram More, G. T. Road,P.O. Asansol , West Bengal-713301.
[7]Assistant Professor, GH Raisoni University, Anjangaon Bari road,Badnera,Amravati (Maharashtra)- 444701.
[8]Assistant Professor, Sanaka Educational Trust's Group of Institutions, Malandighi, Durgapur, West Bengal– 713212.

[*]**Corresponding Author:** Dr. Manisha Masih Singh
[*]Associate Professor, School of Pharmacy, Chouksey Engineering College, Lal khadan, Masturi road, Bilaspur, Chhattisgarh-Pin code - 495004. Email: manishamasih85@gmail.com

Citation: Dr. Manisha Masih Singh et al. (2024), Characterization And In Vivo Efficacy Of Conamax-Derived Antibody Drug Conjugates In Preclinical Cancer Models, *Educational Administration: Theory and Practice*, *30*(5), 7984-7992, Doi: 10.53555/kuey.v30i5.4285

ARTICLE INFO | **ABSTRACT**

Treatments for cancer have advanced significantly over the last fifty years, and in addition to conventional chemotherapy, new treatments include radiation therapy, small-molecule-based targeted therapies, and monoclonal antibodies (mAbs). Despite the fact that these medications have significantly improved the prognosis for cancer patients, their off-target cytotoxicity usually causes detrimental side effects. An antibody-drug conjugate (ADC) combines the potent cytotoxic effects of chemotherapy medications with the specificity of monoclonal antibodies (mAbs) to provide a potential replacement. An ADC consists of three main components: an antibody, a linker, and a cytotoxic payload. The cancer cells are killed by the cytotoxic payload, specific antigens on the cancer cells are targeted by the antibody, and the linker controls the release of the medicine. This targeted approach aims to increase treatment effectiveness while lowering systemic toxicity. Currently, the FDA has authorised nine ADCs, and several more are undergoing clinical development. Recent advancements in ADC technology have improved target selection, linker chemistry, and payload efficacy. These innovations have also raised the therapeutic index and expanded the range of cancers that may be treated. Employing characterisation techniques such as mass spectrometry and chromatography is crucial in ensuring the stability, drug loading, and efficacy of ADC. As ADC technology advances, it has the potential to dramatically change the way cancer is treated by providing safer and more efficient therapy options.

Keywords: ADC Characterization, Cancer Treatment, In Vivo Efficacy, Preclinical Cancer Models, Conamax, Antibody-Drug Conjugates (ADCs)

1. INTRODUCTION

Over the most recent fifty years, propels in cancer therapy and treatment have been made. Chemotherapy, radiation therapy, and targeted meds containing little particles or monoclonal antibodies are options in contrast to a medical procedure for the elimination of tumors in cancer treatment. So far, these treatments have been underlined as more secure and more viable substitutes for traditional chemotherapy [1]. Chemotherapeutic drugs decline the limit of cancer cells to multiply by obstructing numerous mechanisms, including the combination of DNA, microtubule movement, and post-translational protein creation. Nonetheless, serious unfriendly impacts resulting from off-target cytotoxicity might make patients less loyal and potentially quit their medicine. Research indicates that a great deal of human tumors express certain cell surface antigens, which offers a chance to focus on the particular antigen utilizing monoclonal antibody therapy. Paul Ehrlich is credited with coining the expression "sorcery slugs" to depict the utilization of antibodies. Monoclonal antibodies (mAbs) are first delivered from murine or fanciful antibodies to target antigens that cause cancer. In any case, mAbs generally disapprove of target cell entrance, increased immunogenic reactivity, and confined therapeutic productivity because of their colossal size. Advancements, for example, antibody-intervened targeted delivery and recombinant engineering have been proposed as effective methods for addressing these issues [2]. Recombinant engineering method has created new hereditary combinations that are valuable to medicine. Similarly, cytotoxic drugs and monoclonal antibodies might be combined artificially to make target-explicit infection delivery agents. A synergistic effect is guessed when cytotoxic payload and mAb therapy are combined. Monoclonal antibodies can explicitly bind to antigens on the outer layer of tumor cells and induce cell demise through different mechanisms, for example, (a) disrupting cell cycles to induce apoptosis [3]; (b) altering Lymphocyte capability through supplement subordinate cytotoxicity, antibody-subordinate cell cytotoxicity, or supplement subordinate cytotoxicity; and (c) blocking the development of tumor vasculature and stroma. A clever way to deal with treating cancer is the utilization of antibody-drug conjugates, which include attaching tiny chemotherapeutic synthetic compounds to either refined or non-acculturated monoclonal antibodies. A regular ADC comprises of three parts: the mAb, a linker, and the cytotoxic payload (Figure 1). The antibody part of an ADC explicitly focuses on an antigen that is altogether overexpressed in cancer cells [4].



Figure 1: The nature of an antibody drug combination and its three primary components' rational design

Cleavable or noncleavable linkers, which are painstakingly intended to give ideal capacity soundness and drug discharge characteristics, are utilized to link a cytotoxic medicine to the antibody. By using this innovation, the administration of exceptionally cytotoxic meds to cancer cells might be more targeted, resulting in an expansive treatment window. Early studies on treating intense dismissal in kidney relocate patients utilized monoclonal and polyclonal antibody therapy that targeted the antigens, with positive outcomes [5].
The created ADCs will have many medicinal applications and will treat ailment in various ways. Moreover, the intracellular destination of ADCs is basic to their efficacy since these transporters are intended to convey certain substances (such drugs and antibodies) to the cytosol, core, or other explicit intracellular locales. Notwithstanding this, ADC transport and section into cells remain major challenges [6] [7]. When zwitterionic ADCs arrive at a low pH of around 6.8, they might lose their anionic part and leave a positive charge on their surface, which can make it simpler for development cells to enter by means of endocytosis pathways. The ADCs' size and condition will influence target-unequivocal transport. Since to PEGylating innovation, particles less than 100 nm will be less inclined to be discarded, have a more drawn out course, and retain less RES. There could be no more prominent natural importance for the electrostatic participation of accused ADCs of the cell layer. The charged ADCs teamed up more thermodynamically than their uncharged partners. In addition, the unequivocally charged ADCs' bond to the phone film might add to the uniqueness of layer wrapping. The decidedly charged ADCs had a more perceptible and tricky impact on the bilayers of the cell layer. Anionic ADC

grip meaningfully affects layer structure. Along these lines, decidedly charged species will show more toxicity and adverse consequences than adversely charged and unbiased creatures. The administration of drugs using receptor-targeted dynamic targeting has been broadly researched [8].
Of the about 35 antibody-drug conjugates (ADCs) under clinical preliminaries, the FDA has just approved four of them up until this point. In 2000, the FDA endorsed Gemtuzumab ozogamicin, often alluded to as Mylotarg, as the main ADC. It was suggested for individuals with recently analyzed CD33-positive intense myeloid leukemia (AML) as well concerning those two years old and more seasoned who had either backslid from or were impervious to CD33-positive AML. Specifically, CD33 was meant to be the objective. But a clinical trial conducted in 2010 found that this ADC did not raise patient death rates over those of regular cancer treatment, hence it was removed from sale. In 2013, it received additional approval from the FDA. When standard multi-specialist chemotherapy failed to alleviate symptoms of Hodgkin and basic anaplastic large cell lymphomas, the Food and Drug Administration approved brentuximab vedotin. This ADC releases monomethyl auristatin E (MMAE) after targeting CD30 via a protease-cleavable linker. For the treatment of HER2-positive metastatic breast cancer, the FDA approved T-DM1, also known as trastuzumab emtansine, in 2013 [9]. T-DM1 is an amalgam of the potent antimicrotubule drug maytansinoid DM1 and the HER2 antibody trastuzumab, which is an adaptable antagonist. Inotuzumab ozogamicin (IO), a cytotoxic specialist belonging to the calicheamicin family, got a permit in 2017. It was intended to treat intense lymphoblastic leukemia (Everything) that had backslid or was impervious to therapy. It targets CD22.

2. ADC'S STRUCTURE AND MODE OF ACTION

Linkers covalently synthesise cytotoxic medicines, because ADCs are involved in payloads and mAb. Research on ADCs use flow progressions to guarantee minimum immunogenicity, a long half-life in the human circulatory system, and high cell target selectivity.
If you want to build the perfect ADC, you need to know what goes into it first. The main components of ADCs are shown in Figure 1. The ideal ADC would be able to preserve the monoclonal antibody's natural selectivity and ability to target cancer cells while delivering the deadly synthetic chemicals. Since each move toward an ADC strategy is significant, designing the ADCs and producing the epicted schematic portrayal found in Figure 2 is troublesome. In request to safeguard the monoclonal antibody (mAb) from debasement welcomed on by stomach acridity and proteolytic chemicals including proteinase, peptidase, and protease, intravenous administration is typically suggested [10]. The mAb's ADC part binds to target-explicit antigens in target threatening cells all the more actually when it has had longer blood course.
The thinnest linkers can balance out in the circulatory system and release a cytotoxic compound on cancer cells. At the point when a monoclonal antibody (mAb) binds to the outer layer of cancerous cells, an antigen-antibody (Ag-Stomach muscle) complex is shaped. The cell then internalizes this complex by receptor-interceded endocytosis. Clathrin-intervened endocytosis is an essential interaction that structures early endosomes. At the point when hydrogen particles enter the early endosome and ferment it, there is an increased interaction between the mAb part of various ADCs and human neonatal Fc receptors (FcRns). Regular pH is 7.4, which renders it inappropriate for ADC binding to solid, ordinary cells. The framework has a buffering highlight that forestalls delivery issues. FcRn is the main modulator of endosomal articulation. Then, unbound FcRn receptors produce endosomes. Thus, they continue by means of the course of lysosomal breakdown, wherein cytotoxic drugs are delivered into the cytoplasm. This is a significant stage [11]. To maintain drug fixation at the cell level and upgrade drug breakdown, a proper limit should be made. Numerous cytotoxic drugs capability by cleaving the applicable proteins, which either brings about cell passing or apoptosis.Six The significant benefit of this procedure is that it animates neighboring tumor cells and supports stromal tissue. It is fundamental to pick the objective, mAb, linker, and cytotoxic agents in request to create the ADC.48 The many reasons of ADC resistance have been entirely depicted by Sara García-Alonso et al. through careful conversation.



Figure 2: The way in which an antibody drug combination works

3. ADC Characterization Methods

The three components of an ADC complex are an antibody, a cytotoxic payload, and a linker. A number of adaptable logical methods are required for complete characterisation because of the intricacy of the task [12]. The drug loading limit, free drug content, and ADC monomeric content may be found using division-based techniques such as size-avoidance chromatography, hydrophobic interaction chromatography, and reversed-stage chromatography. To find out where the drug load is distributed by cysteine conjugation, Valliere-Douglass et al. suggested electrospray ionisation mass spectrometry. Researchers are now better able to differentiate between particle and pseudo molecular particles because of this ESI-MS approach. Nevertheless, mass spectra might be used to detect minute alterations at the base. Desalting the ADC with SEC is a part of the unstable portable stage. When doing stability testing, SEC inquiry is the main tool for finding ADC discontinuity. The conjugation type and DAR could be confirmed using a mix of RPC and LCMS. The LCMS technique is often used to minimise heterogeneity in ADCs, whether they are reduced or not, when they have an assigned N-oligosaccharide in the Fc domain. The particles' hydrophobicity makes particle-based separation methods, such RPC and HIC, feasible. Drug distribution, drug load, and heterogeneity may all be studied using RPC. RPC measures the quantity of free medicine in an ADC mix and the ADC security under different limit circumstances. Attaching a counteracting specialist to the drug linker might be described by RPC as heavy or light fastenings. Using HIC is as useful as using RPC to demonstrate the hydrophobic characteristics of the ADCs. Hydrophobicity makes higher DAR ADCs susceptible to HIC detection. [13]utilised hydrophilic interaction chromatography in LC-MS center-up research to describe the ADCETRIS (BV) medicine payload and glycan changes. When it comes to characterising immunological conjugates at the subunit level, HILIC works better than switching stage fluid chromatography. "Peptide mapping" is a further method for investigating the drug-load circulation to individual ADC peptides. Using a peptide planning technique, the atomic structure of protein particles and the specific evidence of surface-uncovered epitopes inside the protein molecule are fundamentally studied. Wang et al. used a peptide planning method to design deliverable peptides on huN901-DM1, a maytansinoid ADC integrated by lysine epsilon amino groups. It is common practice to use enzyme techniques for hydrolysis of the limited N-oligosaccharide inside the Fc domain. Through the use of bioanalytical techniques, it is possible to fully ascertain DAR, total antibody sum, and given free drug. Engineered immunosorbent assays (ELISA) are one way to quantify the quantity of antibodies generated. Finding the target of a free drug is much easier by mass spectrometry. Explicit ligand-based metrics that are consistent with early screening techniques were developed to understand the unique architecture of ADC. By using electrochemiluminescent methods, the binding capacity of efficient ADCs has been evaluated.

4. CONJUGATES ANTIBODY-DRUG: DESIGN AND STRUCTURE

As headways in payloads, conjugation techniques, linker advances, and target choice assisted with resolving early issues, the utilization of ADCs has extended and changed over the long haul (Figure 3) [14].



Figure 3: Structure of the antibody-drug combination.

4.1. Choice of Targets

Non-formed monoclonal antibodies (mAbs) work through different pathways, including invulnerable checkpoint inhibition, signaling interruption, receptor downregulation, supplement subordinate cell-intervened cytotoxicity (CDCC), and antibody-subordinate cell-interceded cytotoxicity (ADCC). ADCs, then again, convey their lethal payload to dangerous cells just when the objective receptor internalizes. Selecting the proper objective antigen is significant for the useful combination of an antibody and drug.
It is ideal for the objective antigen to be broadly communicated on the cell surface in request for the circulating ADC to have the option to reach it. For instance, melanoma cell lines expressing 80,000-280,000 p97 receptors for every cell were delicate to ADC L49-vcMMAF, however cell lines with lower p97 articulation were safe. Be that as it may, different qualities of the objective antigen, such binding affinity and internalization rate, may influence how powerful ADCs are all through a scope of antigen articulation levels. For instance, trastuzumab emtansine (T-DM1) often requires huge degrees of ErbB2 articulation (>2 million receptors for every cell), except gemtuzumab ozogamicin is powerful at somewhat moderate degrees of CD33 articulation (5,000 to 10,000 receptors for each cell). The proficiency of ADCs might be compromised assuming antigen transport inside the cancer cell is obstructed, no matter what the amount of surface articulation [15].
The objective antigen ought to just be communicated minimal in solid tissue and just or specially in cancer cells in request to restrict off-target impacts. Four of the nine endorsed ADCs — bentuximab vedotin, polatuzumab vedotin, inotuzumab ozogamicin, and gemtuzumab ozogamicin — target lineage-explicit markers that are reliably communicated by the objective cell type. This is where CD22, CD33, CD30, and CD79 come in as their respective markers. In addition, the cancer cells should moderately release the goal antigen in order to prevent the antibody from being sequestered away from the target cells.
It is essential that the target antigen really internalises following ADC commitment in order for the antigen-ADC combination to undergo receptor-interceded endocytosis. In order to deliver the cytotoxic payload, it must also travel through the proper intracellular trafficking and breakdown pathways. The different rates of basal and antibody-induced internalisation of target antigens may impact the effectiveness of ADCs. As an example, target cells swiftly internalise antibodies that attach to CD74. For ADCs that targeted slower internalising antigens with extra cytotoxic payloads, preclinical results were comparable to those of the counter CD74 ADC immu-110. Inadequate or inefficient internalisation raises the risk of harm due to ill-advised payload circulation outside the cancer cell [16]. Two additional parameters that impact the internalisation of antigen-ADCs are the binding epitope on the target antigen and the affinity of the ADC for the antigen.
Targeting antigens that are typically disseminated in the dispersion is indicated for preventing sequestration or possible debasement of the ADC in the circulatory system. At present, ADCs used in both clinical and preclinical research target more than fifty distinct antigens.

Table 1: the intended antigens for ADCs in development and clinical studies.

Indication	Targets
Acute myeloid leukaemia	CD25, CD33, CD123 (IL-3Rα), FLT3
Breast cancer	CD25, CD174, CD197 (CCR7), CD205 (Ly75), CD228 (P79, SEMF), c-MET, CRIPTO, ErbB2 (HER2), ErbB3 (HER3), FLOR1 (FRα), Globo H, GPNMB, IGF-1R, integrin β-6, PTK7 (CCK4), nectin-4 (PVRL4), ROR2, SLC39A6 (LIV1A ZIP6)
Bladder cancer	CD25, CD205(Ly75)
Colorectal cancer	CD74, CD174, CD166, CD227 (MUC-1), CD326 (Epcam), CEACAM5, CRIPTO, FAP, ED-B, ErbB3 (HER3)
Gastric cancer	CD25, CD197 (CCR7), CD228 (P79, SEMF), FLOR1(FRα), Globo H, GRP20, GCC, SLC39A6 (LIV1A ZIP6)
Gliomas GIII and GIV	CD25, EGFR
Head and neck cancer	CD71 (transferrin R), CD197 (CCR7), EGFR, SLC39A6 (LIV1A ZIP6)
Hodgkin's lymphoma	CD25, CD30, CD197 (CCR7)
Lung cancer	Axl, alpha v beta6, CD25, CD56, CD71 (transferrin R), CD228 (P79, SEMF), CD326, CRIPTO, EGFR, ErbB3 (HER3), FAP, Globo H, GD2, IGF-1R, integrin β-6, mesothelin, PTK7 (CCK4), ROR2, SLC34A2 (NaPi2b), SLC39A6 (LIV1A ZIP6)
Liver cancer	CD276 (B7-H3), c-MET
Melanoma	CD276 (B7-H3), GD2, GPNMB, ED-B, PMEL 17, endothelin B receptor
Mesothelioma	Mesothelin, CD228 (P79, SEMF)
Multiple Myeloma	CD38, CD46 (MCP), CD56, CD74, CD138, CD269 (BCMA), endothelin B receptor
Non-Hodgkin Lymphoma	CD19, CD20, CD22, CD25, CD30, CD37, CD70, CD71 (transferrin R), CD72, CD79, CD180, CD205 (Ly75), ROR1
Ovarian cancer	CA125(MUC16), CD142 (TF), CD205 (Ly75), FLOR1(FRα), Globo H, mesothelin, PTK7 (CCK4)
Pancreatic cancer	CD25, CD71 (transferrin R), CD74, CD227 (MUC1), CD228 (P79, SEMF), GRP20, GCC, IGF-1R, integrin β-6, nectin-4 (PVRL4), SLC34A2 (NaPi2b), SLC44A4, alpha v beta6, mesothelin

4.2. Selection of Antibody

Finding the right antibody could affect the ADC's efficacy, therapeutic index, and pharmacokinetic and pharmacodynamic characteristics. An ADC's ideal monoclonal antibody (mAb) would have a strong affinity for its target and be target explicit. Additionally, it should be highly internalizable, have a low immunogenicity, and a long plasma half-life [17]. To begin with, there are five primary types of human antibodies: IgA, IgD, IgE, IgG, and IgM. The effector activities and heavy chain geographies of these closely related immunoglobulins are distinct. As for the carbohydrates, they contain 4–18% and 82% protein. IgA is further subdivided into IgA1 and IgA2. The immune system's IgG subclasses are IgG1, IgG2, IgG3, and IgG4. Researchers have concentrated on creating medicines that target the IgG class specifically because of the advantages associated with this class. Two heavy chains and two light chains make up an IgG antibody. It includes a stable component (Fc) that interacts with effector cells of the resistant framework and two antigen-binding portions (Fabs) for antigen recognition. The Fc portion interacts with the neonatal Fc receptor for IgG, or FcRn, to control the antibody's half-life accessible for usage. The IgG1 subtype is often contemplated for antibody therapy because of its serum strength and binding affinity for Fc receptors. The Fc district's significance to an ADC varies situational, although Fc-quiet mAbs are relying on more and more ADCs. The attachment of Fcγ might lead to undesirable results. As an example, thrombocytopenia is caused by megakaryocyte internalisation after T-DM1 binds to FcγRIIa. In addition, a stage I inquiry using LOP628 (a c-Pack IgG1 antibody produced to maytansine) terminated LOP628's continued development after binding to pole cells elicited excessive touchiness responses in persons treated with another ADC, FcγR1 and FcγRII. The capacity of IgG2 and IgG4 to induce the supplement overflow is diminished. TR 1801-ADC, which is dependent on a c-Met IgG2 antibody, is now participating in stage I clinical trials. If effector capacity enrollment is not necessary, IgG4 is the optimal protein to deliver ADCs. While IgG1 antibodies attach more strongly to FcγR than IgG4 antibodies, IgG4 antibodies may still bind to FcηRIIIa in its non-fucosylated form. Because of IgG4 antibodies, gemtuzumab ozogamicin and inotuzumab ozogamicin were able to be developed.

Table 2: lists the FDA-approved antibody-drug conjugates for use in clinical settings.

Payload	Target Antigen	Antibody–Drug Conjugates	Antibody	Drug to Antibody Ratio	Linker	Approved Indications	Year of FDA Approval	Year of EMA Approval
Calicheamicin derivative	CD22	Inotuzumab ozogamicin (Besponsa)	Recombinant humanized IgG4	5–7	Acid-labile hydrazone-based linker	B cell precursor ALL	2017	2017
	CD33	Gemtuzumab ozogamicin (Mylotarg)	Humanized IgG4	2–3	Acid-labile hydrazone-based linker	CD33-positive AML	2000 (withdrawn 2010); reapproved 2017	2018
DM1	ErbB2	Trastuzumab emtansine (T-DM1, Kadcyla),	Humanized IgG1	3.5	Non-cleavable thioether linker	ErbB2-positive metastatic breast cancer	2013	2013
MMAE	CD30	Brentuximab vedotin (SGN-35, Adcetris)	Chimeric IgG1	4	Protease-cleavable linker	Hodgkin's lymphoma, ALCL, PTCL, mycosis fungoides	2011	2012
	CD79	Polatuzumab vedotin (Polivy)	Humanized IgG1	4	Protease-cleavable linker	DLBCL	2019	Not approved by the EMA
	Nectin-4	Enfortumab vedotin (ASG-22ME, Padcev)	Human IgG1	4	Cleavable valine-citrulline linker	Advanced urothelial cancer	2019	Not approved by the EMA
MMAF	BCMA	Belantamab mafodotin (GSK2857916, Blenrep)	Humanized IgG1	Unknown	Non-cleavable maleimidocaproyl (mc) linker	Relapsed/refractory multiple myeloma	2020	Orphan drug designation by the EMA, 2017
DXd (DX-8951 derivative)	ErbB2	Trastuzumab deruxtecan (DS-8201a, Enhertu)	Humanized IgG1	8	Cleavable peptide linker	Metastatic ErbB2-positive breast cancer	2019	Not approved by the EMA

4.3. In Clinical Development, Promising ADCs

In spite of the way that there are just nine guaranteed ADCs, ADC configuration has made considerable progress. In excess of 80 ADCs are currently undergoing clinical development in various locales of the globe (Table 3) [18]. ADCs are leading the way in the up and coming age of foundational therapeutic choices for cancer patients. Researchers and specialists are choosing fitting objective antigens, monoclonal antibodies, liners, and cytotoxic payloads in light of the information gained from the clinical development of endorsed ADCs.

Table 3. Antibody–drug conjugates in clinical development.

Payload	Target Antigen	Antibody–Drug Conjugates	Antibody	Linker	Lead Indication	Trial Phase	ClinicalTrials.gov Identifier
AGD-0182	FLT3	AGS62P1 (ASP1235)	Human IgG1	Non-cleavable linker	Acute myeloid leukaemia (AML)	I	NCT02864290
Amberstatin-269	FLT3	AGS-62P1	Humanized IgG1	Cleavable linker	AML	I	NCT02864290
Auristatin-0101	ErbB2	PF-06804103	Humanized IgG1	Protease-cleavable linker	Advanced solid tumors	I	NCT03284723
	PTK7	Cofetuzumab pelidotin PF-7020	Humanized IgG1	Cleavable maleimidoca-proyl -valine-citrulline (mc-vc) PABC linker	Non-small-cell lung cancer (NSCLC), advanced solid tumors	I	NCT04189614 NCT02222922
Auristatin derivative	IGF-1R	W0101	Humanized IgG1	Non-cleavable maleimidoca- proyl (mc) linker	Advanced solid tumors	I/II	NCT0331638
Auristatin	ErbB2	ZW49	Biparatopic IgG	Protease-cleavable linker	ErbB2-expressing cancers	I	NCT03821233
Auristatin F	5T4	ASN-004	Humanized scFvFc antibody	Non-cleavable linker	Advanced solid tumors	I	NCT04410224
Auristatin F-HPA (DolaLock)	SLC34A2 (NaPi2b)	XMT-1592	Humanized IgG1	Protease-cleavable linker	NSCLC, ovarian cancer	I/II	NCT04396340
	SLC34A2 (NaPi2b)	XMT-1536	Humanized IgG1	Protease-cleavable linker	NSCLC, ovarian cancer	I	NCT03319628
Batansine	ErbB2	BAT8001	Humanized IgG1	Non-cleavable linker	Metastatic breast cancer	I	NCT04189211 NCT04151329
	TROP2	BAT8003	IgG1	Non-cleavable linker	Advanced epithelial cancer	I	NCT03884517

5. CONCLUSION

The development and use of antibody-drug conjugates, which provide targeted treatment alternatives combining the potency of cytotoxic medicines with the selectivity of monoclonal antibodies, has significantly improved cancer therapy [19] [20]. As of right now, the FDA has authorised nine ADCs for various cancer types because to their excellent preclinical and clinical results. The efficiency of ADCs depends on the careful selection of target antigens, antibody selection, linker and payload design. ADCs are a helpful weapon in the battle against cancer because of the improvements in safety and effectiveness profiles brought about by these breakthroughs. Characterization techniques like as mass spectrometry and chromatography are critical to the success and stability of ADCs. Despite the challenging process of developing ADCs, recent research and clinical trials are expanding their potential and holding out hope for safer and more efficient cancer therapies. Future cancer therapy is anticipated to be significantly impacted by ADC technology, which offers new avenues for targeted treatment and better patient results.

REFERENCES

1. Abrams, T., Connor, A., Fanton, C., Cohen, S. B., Huber, T., Miller, K., ... & Schleyer, S. C. (2018). Preclinical antitumor activity of a novel anti–c-KIT antibody–drug conjugate against mutant and wild-type c-KIT–positive solid tumors. Clinical Cancer Research, 24(17), 4297-4308.
2. Abu-Yousif, A. O., Cvet, D., Gallery, M., Bannerman, B. M., Ganno, M. L., Smith, M. D., ... & Veiby, O. P. (2020). Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts. Molecular Cancer Therapeutics, 19(10), 2079-2088.
3. Agarwal, S., Fang, L., McGowen, K., Yin, J., Bowman, J., Ku, A. T., ... & Kelly, K. (2023). Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. The Journal of Clinical Investigation, 133(22).
4. Bornstein, G. G. (2015). Antibody drug conjugates: preclinical considerations. The AAPS journal, 17, 525-534.
5. Challita-Eid, P. M., Satpayev, D., Y
6. ang, P., An, Z., Morrison, K., Shostak, Y., ... & Stover, D. R. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.
7. Decary, S., Berne, P. F., Nicolazzi, C., Lefebvre, A. M., Dabdoubi, T., Cameron, B., ... & Blanc, V. (2020). Preclinical activity of SAR408701: a novel anti-CEACAM5–maytansinoid antibody–drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clinical Cancer Research, 26(24), 6589-6599.
8. Haddish-Berhane, N., Shah, D. K., Ma, D., Leal, M., Gerber, H. P., Sapra, P., ... & Betts, A. M. (2013). On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. Journal of pharmacokinetics and pharmacodynamics, 40, 557-571.
9. Hedrich, W. D., Fandy, T. E., Ashour, H. M., Wang, H., & Hassan, H. E. (2018). Antibody–drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clinical pharmacokinetics, 57, 687-703.
10. Kamath, A. V., & Iyer, S. (2015). Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharmaceutical research, 32, 3470-3479.
11. Kendsersky, N. M., Lindsay, J., Kolb, E. A., Smith, M. A., Teicher, B. A., Erickson, S. W., ... & Maris, J. M. (2021). The B7-H3–targeting antibody–Drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. Clinical Cancer Research, 27(10), 2938-2946.
12. Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., ... & Law, C. L. (2016). Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer research, 76(9), 2710-2719.
13. Li, H., Zhang, X., Xu, Z., Li, L., Liu, W., Dai, Z., ... & Hu, C. (2021). Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antibody therapeutics, 4(3), 175-184.
14. Lin, K., Rubinfeld, B., Zhang, C., Firestein, R., Harstad, E., Roth, L., ... & Polakis, P. (2015). Preclinical development of an anti-NaPi2b (SLC34A2) antibody–drug conjugate as a therapeutic for non–small cell lung and ovarian cancers. Clinical Cancer Research, 21(22), 5139-5150.
15. Lucas, A. T., Robinson, R., Schorzman, A. N., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2019). Pharmacologic considerations in the disposition of antibodies and antibody-drug conjugates in preclinical models and in patients. Antibodies, 8(1), 3.
16. Perrone, E., Lopez, S., Zeybek, B., Bellone, S., Bonazzoli, E., Pelligra, S., ... & Santin, A. D. (2020). Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer. Frontiers in Oncology, 10, 118.

17. Scribner, J. A., Brown, J. G., Son, T., Chiechi, M., Li, P., Sharma, S., ... & Loo, D. (2020). Preclinical development of MGC018, a duocarmycin-based antibody–drug conjugate targeting B7-H3 for solid cancer. Molecular Cancer Therapeutics, 19(11), 2235-2244.
18. Sommer, A., Kopitz, C., Schatz, C. A., Nising, C. F., Mahlert, C., Lerchen, H. G., ... & Kreft, B. (2016). Preclinical efficacy of the auristatin-based antibody–drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer Research, 76(21), 6331-6339.
19. Strop, P., Tran, T. T., Dorywalska, M., Delaria, K., Dushin, R., Wong, O. K., ... & Liu, S. H. (2016). RN927C, a site-specific trop-2 antibody–drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Molecular cancer therapeutics, 15(11), 2698-2708.
20. Wong, O. K., Tran, T. T., Ho, W. H., Casas, M. G., Au, M., Bateman, M., ... & Liu, S. H. (2018). RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. Oncotarget, 9(71), 33446.
21. Zammarchi, F., Havenith, K. E., Chivers, S., Hogg, P., Bertelli, F., Tyrer, P., ... & van Berkel, P. H. (2022). Preclinical development of ADCT-601, a novel pyrrolobenzodiazepine dimer-based antibody–drug conjugate targeting AXL-expressing cancers. Molecular Cancer Therapeutics, 21(4), 582-593.